Effects of different corticosteroids on the development of osteonecrosis in rabbits

Rheumatology

Volumn 44, Issue 3, 2005, Pages 332-336

  Miyanishi, K ^a   Yamamoto, T ^a   Irisa, T ^a   Motomura, G ^a   Jingushi, S ^a   Sueishi, K ^b   Iwamoto, Y ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Corticosteroid; Hip; Osteonecrosis; Rabbit

Indexed keywords

CHOLESTEROL; CORTICOSTEROID; FATTY ACID; METHYLPREDNISOLONE ACETATE; PREDNISOLONE SODIUM SUCCINATE; TRIACYLGLYCEROL; TRIAMCINOLONE ACETONIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD EXAMINATION; BONE NECROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; FATTY ACID BLOOD LEVEL; FEMUR; FEMUR HEAD NECROSIS; HISTOPATHOLOGY; HUMERUS; INCIDENCE; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHOLESTEROL; FATTY ACIDS, NONESTERIFIED; FEMUR HEAD; FEMUR HEAD NECROSIS; INJECTIONS, INTRAMUSCULAR; MALE; METHYLPREDNISOLONE; PREDNISOLONE; RABBITS; TRIAMCINOLONE ACETONIDE; TRIGLYCERIDES;

EID: 14944342196     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh505     Document Type: Article

References (30)

1. Mankin HJ. Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med 1992;326:1473-9.
2. Lieberman JR, Berry DJ, Mont MA et al. Osteonecrosis of the hip: management in the 21st century. Instr Course Lect 2003;52:337-55.
3. Oinuma K, Harada Y, Nawata Y et al. Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis 2001;60:1145-8.
4. Nagasawa K, Ishii Y, Mayumi T et al. Avascular necrosis of bone in systemic lupus erythematosus: possible role of haemostatic abnormalities. Ann Rheum Dis 1989;48:672-6.
5. USPDI. Corticosteroids - Glucocorticoid effects (systemic). In: Drug information for the health care professional. Greenwood Village: Micromedex Thomson Healthcare, 2002:1002-27.
6. Badsha H, Edwards CJ. Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Semin Arthritis Rheum 2003;32:370-7.
7. Albert DA, Hadler NM, Ropes MW. Does corticosteroid therapy affect the survival of patients with systemic lupus erythematosus? Arthritis Rheum 1979;22:945-53.
8. Yamamoto T, Irisa T, Sugioka Y, Sueishi K. Effects of pulse methylprednisolone on bone and marrow tissues: corticosteroid-induced osteonecrosis in rabbits. Arthritis Rheum 1997;40:2055-64.
9. Doggrell SA. Triamcinolone: new and old indications. Expert Opin Pharmacother 2001;2:1177-86.
10. Miyanishi K, Yamamoto T, Irisa T et al. A high low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio as a potential risk factor for corticosteroid-induced osteonecrosis in rabbits. Rheumatology 2001;40:196-201.
11. Melby JC. Drug spotlight program: systemic corticosteroid therapy: pharmacology and endocrinologic considerations. Ann Intern Med 1974;81:505-12.
12. Neidel J, Boehnke M, Kuster RM. The efficacy and safety of intraarticular corticosteroid therapy for coxitis in juvenile rheumatoid arthritis. Arthritis Rheum 2002;46:1620-8.
13. Nasser SMS, Ewan PW. Depot corticosteroid treatment for hay fever causing avascular necrosis of both hips. BMJ 2001;322:1589-91.
14. Jones LC, Mont MA, Le TB et al. Procoagulants and osteonecrosis. J Rheumatol 2003;30:783.
15. Mont MA, Glueck CJ, Pacheco IH, Wang P, Hungerford DS, Petri M. Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol 1997;24:654-62.
16. Wing PC, Nance P, Connell DG, Gagnon F. Risk of avascular necrosis following short term megadose methylprednisolone treatment. Spinal Cord 1998;36:633-6.
17. Miyanishi K, Yamamoto T, Irisa T et al. Bone marrow fat cell enlargement and a rise in intraosseous pressure in steroid-treated rabbits with osteonecrosis. Bone 2002;30:185-90.
18. Boskey AL, Raggio CL, Bullough PG, Kinnett JG. Changes in the bone tissue lipids in persons with steroid- and alcohol-induced osteonecrosis. Clin Orthop 1983;172:289-95.
19. Zizic TM, Marcoux C, Hungerford DS, Stevens MB. The early diagnosis of ischemic necrosis of bone. Arthritis Rheum 1997; 40:2055-64.
20. Arlet J, Durroux R, Fauchier C, Thiechart M. Histopathology of nontraumatic necrosis of the femoral head: topographic and evolutive aspects. In: Arlet J, Ficat RP, Hungerford DS, eds. Bone Circulation. Baltimore: Williams & Wilkins, 1984:296-305.
21. Miyanishi K, Yamamoto T, Irisa T, Noguchi Y, Sugioka Y, Iwamoto Y. Increased level of apolipoprotein B/apolipoprotein A1 ratio as a potential risk for osteonecrosis. Ann Rheum Dis 1999;58:514-6.
22. Garber EK, Bluestone R. Realistic guidelines of corticosteroid therapy in rheumatic disease. Semin Arthritis Rheum 1981;11: 231-56.
23. Waddell AW, Currie AR. A comparison of the effects of prednisolone and methylprednisolone on human lymphoblastoid cells. Biochem J 1977;168:323-4.
24. Szefler S. General pharmacology. In: Schleimer RP, editor. Anti-inflammatory steroid action of glucocorticoids. San Diego: Academic Press, 1989:353-76.
25. Uribe M, Go VL. Corticosteroid pharmacokinetics in liver disease. Clin Pharmacokinet 1979;4:233-40.
26. Mingrone G, DeGaetano A, Pugeat M, Capristo E, Greco AV, Gasbarrini G. The steroid resistance of Crohn's disease. J Investig Med 1999;47:319-25.
27. Szeffer SJ, Ebling WF, Georgitis JW, Jusko WJ. Methylprednisolone versus prednisolone pharmacokinetics in relation to dose in adults. Eur J Clin Pharmacol 1986;30:323-9.
28. Jones JP Jr. Fat embolism, intravascular coagulation, and osteonecrosis. Clin Orthop 1993;292:294-308.
29. Glueck CJ, Freiberg RA, Fontaine RN, Tracy T, Wang P. Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop 2001; 386:19-33.
30. Sheikh JS, Retzinger GS, Hess EV. Association of osteonecrosis in systemic lupus erythematosus with abnormalities of fibrinolysis. Lupus 1998;7:42-8.